ESC Heart Failure

Article	Citations
Heart failure after myocardial infarction: incidence and predictors	289
Machine learning vs. conventional statistical models for predicting heart failure readmission and mortality	101
Congestive nephropathy: a neglected entity? Proposal for diagnostic criteria and future perspectives	94
Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis	85
Sarcopenia in heart failure: a systematic review and meta‐analysis	82
Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock	79
Increased mortality and worse cardiac outcome of acute myocardial infarction during the early COVID‐19 pandemic	74
Cardiogenic shock teams and centres: a contemporary review of multidisciplinary care for cardiogenic shock	61
Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data	55
Iron deficiency in heart failure	55
Heart failure in the last year: progress and perspective	55
SGLT2 inhibitors and cardiac remodelling: a systematic review and meta‐analysis of randomized cardiac magnetic resonance imaging trials	53
Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial	52
‘Time is prognosis’ in heart failure: time‐to‐treatment initiation as a modifiable risk factor	50
Reaching consensus for unified medical language in Fontan care	50
Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic	48
Neutrophil‐to‐lymphocyte ratio and outcomes in patients with new‐onset or worsening heart failure with reduced and preserved ejection fraction	47
Hospital readmissions of patients with heart failure from real world: timing and associated risk factors	47
Heart failure related to adult congenital heart disease: prevalence, outcome and risk factors	40
Cardiac performance in patients hospitalized with COVID‐19: a 6 month follow‐up study	39
Heart failure: an update from the last years and a look at the near future	37
Clinical phenogroups are more effective than left ventricular ejection fraction categories in stratifying heart failure outcomes	36
Baseline characteristics, management, and predictors of early mortality in cardiogenic shock: insights from the FRENSHOCK registry	36
Advanced heart failure: guideline‐directed medical therapy, diuretics, inotropes, and palliative care	36
Real‐world evidence in a national health service: results of the UK CardioMEMS HF System Post‐Market Study	34

Thromboembolism and bleeding in systemic amyloidosis: a review	34
Early use of remote dielectric sensing after hospitalization to reduce heart failure readmissions	34
Heart failure is associated with an increased incidence of cancer diagnoses	34
Fibrosis‐4 index reflects right ventricular function and prognosis in heart failure with preserved ejection fraction	34
A year in heart failure: an update of recent findings	33
Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature	33
Blood urea nitrogen to serum albumin ratio as a new prognostic indicator in critical patients with chronic heart failure	33
Sacubitril/valsartan in real‐life European patients with heart failure and reduced ejection fraction: a systematic review and meta‐analysis	33
Home‐based cardiac rehabilitation using information and communication technology for heart failure patients with frailty	32
Sodium‐glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta‐analysis	31
ACC/AHA/HFSA 2022 and ESC 2021 guidelines on heart failure comparison	31
Myocardial injury in severe COVID‐19 is similar to pneumonias of other origin: results from a multicentre study	31
Efficacy and safety of intermittent repeated levosimendan infusions in advanced heart failure patients: the LAICA study	30
The diagnostic and prognostic value of galectin‐3 in patients at risk for heart failure with preserved ejection fraction: results from the DIAST‐CHF study	30
Predictive value of H2FPEF score in patients with heart failure with preserved ejection fraction	30
Meta‐analysis of echocardiographic quantification of left ventricular filling pressure	30
The impact of frailty according to Clinical Frailty Scale on clinical outcome in patients with heart failure	29
Colchicine prevents disease progression in viral myocarditis via modulating the NLRP3 inflammasome in the cardiosplenic axis	29
SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta‐analysis	29
Safety and efficacy of a wireless pulmonary artery pressure sensor: primary endpoint results of the SIRONA 2 clinical trial	29
Clinical and economic impact of HeartLogic™ compared with standard care in heart failure patients	29
Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction	29
Prognostic significance of the HFA‐PEFF score in patients with heart failure with preserved ejection fraction	29
Patient monitoring across the spectrum of heart failure disease management 10 years after the CHAMPION trial	28
Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT	28
Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy	28
Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study	27
Smoking and heart failure: a Mendelian randomization and mediation analysis	27
The evidence for pharmacist care in outpatients with heart failure: a systematic review and meta‐analysis	27
Cardiac adaptations to 60 day head‐down‐tilt bed rest deconditioning. Findings from the AGBRESA study	27
Full spectrum of clonal haematopoiesis‐driver mutations in chronic heart failure and their associations with mortality	27
Implication of inhaled nitric oxide for the treatment of critically ill COVID‐19 patients with pulmonary hypertension	26
Heart failure in COVID‐19: the multicentre, multinational PCHF‐COVICAV registry	26
Prognostic factors of Takotsubo cardiomyopathy: a systematic review	26
Insulin‐like growth factor binding protein 7 (IGFBP7), a link between heart failure and senescence	26
The impact of COVID‐19 on the management of heart failure: a United Kingdom patient questionnaire study	25
Clinical presentation and long‐term outcomes of infantile hypertrophic cardiomyopathy: a European multicentre study	25
Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction	25
Patient profile and outcomes associated with follow‐up in specialty vs. primary care in heart failure	25
Echocardiographic and clinical predictors of cardiac amyloidosis: limitations of apical sparing	25
Predicting Parameters for Successful Weaning from Veno‐Arterial Extracorporeal Membrane Oxygenation in Cardiogenic Shock	25
Applying the ESC 2016, H2FPEF, and HFA‐PEFF diagnostic algorithms for heart failure with preserved ejection fraction to the general population	25
Predictors and prognosis of right ventricular function in pulmonary hypertension due to heart failure with reduced ejection fraction	25
The prognostic value of serial troponin measurements in patients admitted for COVID‐19	25
Visceral adiposity, muscle composition, and exercise tolerance in heart failure with preserved ejection fraction	25
Clinical profile and midterm prognosis of left ventricular thrombus in heart failure	25
Non‐alcoholic fatty liver disease and heart failure with preserved ejection fraction: from pathophysiology to practical issues	25
Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction	25
Impact of change in iron status over time on clinical outcomes in heart failure according to ejection fraction phenotype	25
99mTechnetium‐pyrophosphate scintigraphy: a practical guide for early diagnosis of transthyretin amyloid cardiomyopathy	24

Epidemiology of cardiogenic shock and cardiac arrest complicating non‐ST‐segment elevation myocardial infarction: 18‐year US study	24
Machine learning‐based model for predicting 1 year mortality of hospitalized patients with heart failure	24
Current patterns of beta‐blocker prescription in cardiac amyloidosis: an Italian nationwide survey	24
Left atrial function and maximal exercise capacity in heart failure with preserved and mid‐range ejection fraction	24
Prevalence and prognostic impact of cognitive frailty in elderly patients with heart failure: sub‐analysis of FRAGILE‐HF	24
Prognostic value of lung ultrasound in patients hospitalized for heart disease irrespective of symptoms and ejection fraction	24
Myocardial work index: a marker of left ventricular contractility in pressure‐ or volume overload‐induced heart failure	24
Clinical profile and 90 day outcomes of 10 851 heart failure patients across India: National Heart Failure Registry	24
Adaptive versus maladaptive right ventricular remodelling	24
Iron deficiency in heart failure patients: the French CARENFER prospective study	23
Insights into heart failure hospitalizations, management, and services during and beyond COVID‐19	23
The impact of platelet indices on clinical outcome in heart failure: results from the MyoVasc study	23
Identification of novel circulating microRNAs in advanced heart failure by next‐generation sequencing	23
Crosstalk between the activated Slit2–Robo1 pathway and TGF‐β1 signalling promotes cardiac fibrosis	23
Impact of telemedicine on the management of heart failure patients during coronavirus disease 2019 pandemic	23
A novel echocardiographic method for estimation of pulmonary artery wedge pressure and pulmonary vascular resistance	23
Intravenous iron infusion in patients with heart failure: a systematic review and study‐level meta‐analysis	23
Impact analysis of heart failure across European countries: an ESC‐HFA position paper	23
Derivation of an electronic frailty index for predicting short‐term mortality in heart failure: a machine learning approach	23
Prognostic impact of hospital‐acquired disability in elderly patients with heart failure	23
High‐sensitivity cardiac troponin T determines all‐cause mortality in cancer patients: a single‐centre cohort study	22
Phenylacetylglutamine as a risk factor and prognostic indicator of heart failure	22
A standardized definition for right ventricular failure in cardiac surgery patients	22
Chronic exogenous ketone supplementation blunts the decline of cardiac function in the failing heart	22
Sex differences in patients with cardiogenic shock	22
Prognostic impact of Clinical Frailty Scale in patients with heart failure with preserved ejection fraction	22
Admission NT‐proBNP and outcomes in patients without history of heart failure hospitalized with COVID‐19	22
Characteristics and outcomes of heart failure with recovered left ventricular ejection fraction	22
Copeptin as a predictive marker of incident heart failure	22
Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension	22
Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction	22
Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry	22
Clinical characteristics and frailty status in heart failure with preserved vs. reduced ejection fraction	22
Acute myocarditis after COVID‐19 vaccination with mRNA‐1273 in a patient with former SARS‐CoV‐2 infection	22
Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR‐ACT	22
Impact of COVID‐19 pandemic on acute heart failure admissions and mortality: a multicentre study (COV‐HF‐SIRIO 6 study)	22
Spot urine sodium in acute heart failure: differences in prognostic value on admission and discharge	22
Effect of angiotensin receptor neprilysin inhibitors on left atrial remodeling and prognosis in heart failure	22
Impact of COVID‐19 on inpatient referral of acute heart failure: a single‐centre experience from the south‐west of the UK	22
Incident heart failure and myocardial infarction in sodium‐glucose cotransporter‐2 vs. dipeptidyl peptidase‐4 inhibitor users	21
Abnormal P‐wave terminal force in lead V1 is a marker for atrial electrical dysfunction but not structural remodelling	21
Five‐year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort	21
Time‐sensitive approach in the management of acute heart failure	21
Complications of left ventricular assist devices causing high urgency status on waiting list: impact on outcome after heart transplantation	21
Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial	21
Diagnostic and prognostic implications of heart failure with preserved ejection fraction scoring systems	21
High‐protein vs. standard‐protein diets in overweight and obese patients with heart failure and diabetes mellitus: findings of the Pro‐HEART trial	21
Heart failure with preserved, mid‐range, and reduced ejection fraction across health care settings: an observational study	20
Left atrial strain predicts exercise capacity in heart failure independently of left ventricular ejection fraction	20
Late phase of COVID‐19 pandemic in General Cardiology. A position paper of the ESC Council for Cardiology Practice	20
Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal tunnel surgery	20
MicroRNA profiling as a novel diagnostic tool for identification of patients with inflammatory and/or virally induced cardiomyopathies	20
A global longitudinal strain cut‐off value to predict adverse outcomes in individuals with a normal ejection fraction	20
One‐year results following PASCAL‐based or MitraClip‐based mitral valve transcatheter edge‐to‐edge repair	20
Higher BNP/NT‐pro BNP levels stratify prognosis equally well in patients with and without heart failure: a meta‐analysis	20
Self‐care perception and behaviour in patients with heart failure: A qualitative and quantitative study	20
Non‐invasive home telemonitoring in patients with decompensated heart failure: a systematic review and meta‐analysis	20
Effects of the COVID‐19 pandemic on heart failure hospitalizations in Japan: interrupted time series analysis	20
A case series analysis on the clinical experience of Impella 5.5® at a large tertiary care centre	20
Prevalence and prognostic value of the coexistence of anaemia and frailty in older patients with heart failure	20
Digital health in older adults for the prevention and management of cardiovascular diseases and frailty. A clinical consensus statement from the ESC Council for Cardiology Practice/Taskforce on Ger	20
Outflow graft obstruction after left ventricular assist device implantation: a retrospective, single‐centre case series	20
Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries	20
Pleiotropic activity of nerve growth factor in regulating cardiac functions and counteracting pathogenesis	19
SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin	19
Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload	19
Endothelial dysfunction and C‐reactive protein predict the incidence of heart failure in hypertensive patients	19
Clinical features and predictors of atrial fibrillation in patients with light‐chain or transthyretin cardiac amyloidosis	19
Characteristics, treatment, and outcomes of newly diagnosed atrial fibrillation patients with heart failure: GARFIELD‐AF	19
Propensity score‐based analysis of long‐term outcome of patients on HeartWare and HeartMate 3 left ventricular assist device support	19
Use of extracorporeal circulation (ECLS/ECMO) for cardiac and circulatory failure –A clinical practice Guideline Level 3	19
Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry	19
Pathophysiological role of fatty acid‐binding protein 4 in Asian patients with heart failure and preserved ejection fraction	19
Stroke and systemic embolism in patients with atrial fibrillation and heart failure according to heart failure type	19
Trimethylamine N‐oxide and outcomes in patients hospitalized with acute heart failure and preserved ejection fraction	19
A proposed strategy for anticoagulation therapy in noncompaction cardiomyopathy	19
Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients?	19
Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications	19
Vericiguat and NT‐proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial	19
Sacubitril‐valsartan initiation in chronic heart failure patients impacts sleep apnea: the ENTRESTO‐SAS study	19

Influence of catheter ablation for atrial fibrillation on atrial and ventricular functional mitral regurgitation	19
Mortality risk in chronic Chagas cardiomyopathy: a systematic review and meta‐analysis	18
Muscular changes in animal models of heart failure with preserved ejection fraction: what comes closest to the patient?	18
Diagnostic performance of nutritional indicators in patients with heart failure	18
Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST‐WHF in perspective	18
NT‐proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials	18
Ryanodine receptor and immune‐related molecules in diabetic cardiomyopathy	18
Electrocardiographic features and their echocardiographic correlates in peripartum cardiomyopathy: results from the ESC EORP PPCM registry	18
Right ventricular function and its coupling to pulmonary circulation predicts exercise tolerance in systolic heart failure	18
Sacubitril/valsartan in heart failure: efficacy and safety in and outside clinical trials	18
ARNI versus ACEI/ARB in Reducing Cardiovascular Outcomes after Myocardial Infarction	18
Systematic review of sodium‐glucose cotransporter 2 inhibitors: a hopeful prospect in tackling heart failure‐related events	18
Clinical phenotypes, aetiologies, management, and mortality in acute heart failure: a single‐institution study in Latin‐America	18
Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure	18
The effect of high‐flow arteriovenous fistulas on systemic haemodynamics and brain oxygenation	18
Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018	18
WBC count predicts heart failure in diabetes and coronary artery disease patients: a retrospective cohort study	18
Multimodality assessment of heart failure with preserved ejection fraction skeletal muscle reveals differences in the machinery of energy fuel metabolism	18
Late gadolinium enhancement characteristics in giant cell myocarditis	18
The first experience with sodium‐glucose cotransporter 2 inhibitor for the treatment of systemic right ventricular failure	18
Ferric carboxymaltose for the treatment of iron‐deficient heart failure patients: a systematic review and meta‐analysis	18
Heart failure during the COVID‐19 pandemic: clinical, diagnostic, management, and organizational dilemmas	18
Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure	18
Levosimendan in venoarterial ECMO weaning. Rational and design of a randomized double blind multicentre trial	18
Myocarditis following rAd26 and rAd5 vector‐based COVID‐19 vaccine: case report	18
Iron deficiency impacts prognosis but less exercise capacity in heart failure with preserved ejection fraction	18
Myocardial oedema: pathophysiological basis and implications for the failing heart	18
Risk stratification with echocardiographic biomarkers in heart failure with preserved ejection fraction: the media echo score	18
Myocarditis following mRNA COVID‐19 vaccination: call for endomyocardial biopsy	17
Predicting outcome in children with dilated cardiomyopathy: the use of repeated measurements of risk factors for outcome	17
Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice	17
Skeletal muscle atrophy in heart failure with diabetes: from molecular mechanisms to clinical evidence	17
Transcatheter aortic valve replacement in aortic stenosis and cardiac amyloidosis: a systematic review and meta‐analysis	17
Circulating levels and prognostic cut‐offs of sST2, hs‐cTnT, and NT‐proBNP in women vs. men with chronic heart failure	17
Ubiquitin‐proteasome‐system and enzymes of energy metabolism in skeletal muscle of patients with HFpEF and HFrEF	17
Diagnosis of wild‐type transthyretin amyloid cardiomyopathy in Japan: red‐flag symptom clusters and diagnostic algorithm	17
Individual patient data meta‐analysis of the effects of the CARILLON® mitral contour system	17
Plasma amino acid profiling improves predictive accuracy of adverse events in patients with heart failure	17
Systematic review of efficacy of direct oral anticoagulants and vitamin K antagonists in left ventricular thrombus	17
Prevalence and predictors of sleep‐disordered breathing in chronic heart failure: the SchlaHF‐XT registry	17
Impact of primary care involvement and setting on multidisciplinary heart failure management: a systematic review and meta‐analysis	17
Prevalence and determinants of systolic and diastolic cardiac dysfunction and heart failure in acute ischemic stroke patients: The SICFAIL study	17
Systemic immune‐inflammation index as a prognostic marker for advanced chronic heart failure with renal dysfunction	17
Impact of sex differences in co‐morbidities and medication adherence on outcome in 25 776 heart failure patients	16
A practical approach to the guideline‐directed pharmacological treatment of heart failure with reduced ejection fraction	16
A clinical score for predicting left ventricular reverse remodelling in patients with dilated cardiomyopathy	16
Impact of catheter ablation for atrial fibrillation on cardiac disorders in patients with coexisting heart failure	16
Diagnosis and Treatment of Iron Deficiency in Heart Failure: OFICSel study by the French Heart Failure Working Group	16
The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity	16
Atrial cardiomyopathy: from cell to bedside	16
Aetiological classification and prognosis in patients with heart failure with preserved ejection fraction	16
Successful heart transplantation for COVID‐19‐associated post‐infectious fulminant myocarditis	16
Circulating SERPINA3 improves prognostic stratification in patients with a de novo or worsened heart failure	16
Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program	16
Heart failure is independently associated with white matter lesions: insights from the population‐based LIFE‐Adult Study	16
Epinephrine administration in venoarterial extracorporeal membrane oxygenation patients is associated with mortality: a retrospective cohort study	16
Palliative key aspects are of importance for symptom relief during the last week of life in patients with heart failure	16
Multiparameter diagnostic sensor measurements during clinically stable periods and worsening heart failure in ambulatory patients	16
The benefits of sacubitril–valsartan in patients with acute myocardial infarction: a systematic review and meta‐analysis	16
Telocytes‐derived extracellular vesicles alleviate aortic valve calcification by carrying miR‐30b	15
History of extracardiac/cardiac events in cardiac amyloidosis: prevalence and time from initial onset to diagnosis	15
Beyond the stethoscope: managing ambulatory heart failure during the COVID‐19 pandemic	15
Is 24/7 remote patient management in heart failure necessary? Results of the telemedical emergency service used in the TIM‐HF and in the TIM‐HF2 trials	15
Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure	15
Prognostic value of the H2FPEF score in patients undergoing transcatheter aortic valve implantation	15
Eligibility for subcutaneous implantable cardioverter‐defibrillator in adults with congenital heart disease	15
Recurrent heart failure hospitalizations increase the risk of cardiovascular and all‐cause mortality in patients with heart failure in Sweden: a real‐world study	15
Low mechano‐energetic efficiency is associated with future left ventricular systolic dysfunction in hypertensives	15
Extracorporeal life support as bridge to recovery in yew poisoning: case reports and literature review	15
Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure	15
Cardiac MRI predictors of adverse outcomes in adults with a systemic right ventricle	15
Lumican accumulates with fibrillar collagen in fibrosis in hypertrophic cardiomyopathy	15
Exercise‐induced B‐lines in heart failure with preserved ejection fraction occur along with diastolic function worsening	15
Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial	15
Impact of intraventricular haemodynamic forces misalignment on left ventricular remodelling after myocardial infarction	15
Cancer and Takotsubo syndrome: from rarity to clinical practice	15
Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters	15
Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure	15
Association of iron deficiency with incident cardiovascular diseases and mortality in the general population	15
Predictors of long‐term outcome in heart failure with preserved ejection fraction: a follow‐up from the KaRen study	15
The prevalence, predictors, and outcomes of spontaneous echocardiographic contrast or left ventricular thrombus in patients with HFrEF	15
Sudden cardiogenic shock mimicking fulminant myocarditis in a surviving teenager affected by severe acute respiratory syndrome coronavirus 2 infection	15
The potential role of plasma miR‐155 and miR‐206 as circulatory biomarkers in inflammatory cardiomyopathy	15
A systematic review of rehabilitation in chronic heart failure: evaluating the reporting of exercise interventions	15
Mechanosensitive molecular mechanisms of myocardial fibrosis in living myocardial slices	14
Clinical characteristics of people with heart failure in Australian general practice: results from a retrospective cohort study	14
Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction	14
HFA‐PEFF score: prognosis in patients with preserved ejection fraction after transcatheter aortic valve implantation	14
Heart failure with preserved ejection fraction phenogroup classification using machine learning	14
Heart failure and atrial flutter: a systematic review of current knowledge and practices	14
Usefulness of ventilatory inefficiency in predicting prognosis across the heart failure spectrum	14
Endothelial NADPH oxidase 4 protects against angiotensin II‐induced cardiac fibrosis and inflammation	14
MicroRNA‐494 regulates high glucose‐induced cardiomyocyte apoptosis and autophagy by PI3K/AKT/mTOR signalling pathway	14
Can glucose‐lowering medications improve outcomes in non‐diabetic heart failure patients? A Bayesian network meta‐analysis	14
Mortality risk prediction in elderly patients with cardiogenic shock: results from the CardShock study	14